Randomized phase II trial for primary induction therapy in AML using sequential high dose cytosine arabinoside (AraC) and mitoxantrone (S-HAM) and pegylated G-CSF for shortening of therapy-induced neutropenia

Braess, J. and Fiegl, M. and Reichle, A. and Woermann, B. and Oruzio, D. and Staib, P. and Berdel, W. and Heinecke, A. and Hiddemann, W. (2006) Randomized phase II trial for primary induction therapy in AML using sequential high dose cytosine arabinoside (AraC) and mitoxantrone (S-HAM) and pegylated G-CSF for shortening of therapy-induced neutropenia. ANNALS OF HEMATOLOGY, 85 (Suppl1). pp. 28-30. ISSN 0939-5555

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)
Depositing User: Petra Gürster
Date Deposited: 10 Feb 2021 11:34
Last Modified: 10 Feb 2021 11:34
URI: https://pred.uni-regensburg.de/id/eprint/34957

Actions (login required)

View Item View Item
pred is powered by EPrints 3.4 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.